| Texto completo | |
| Autor(es): |
Sposito, Larissa
;
Morais-Silva, Gessynger
;
Fonseca, Diana
;
Neves, Matheus Morais
;
Silva, Murilo Vieira
;
Bauab, Tais Maria
;
Parreira, Paula
;
Martins, M. Cristina L.
;
Meneguin, Andreia Bagliotti
;
Chorilli, Marlus
Número total de Autores: 10
|
| Tipo de documento: | Artigo Científico |
| Fonte: | International Journal of Biological Macromolecules; v. 305, p. 21-pg., 2025-05-01. |
| Resumo | |
Gastric ulcers affect 4 million people worldwide and occur when the stomach's defenses are compromised, allowing harmful agents, such as nonsteroidal anti-inflammatory drugs and Helicobacter pylori, to damage the tissue. The naturally occurring polyphenol, trans-resveratrol (RESV), demonstrates promising potential for treating gastric diseases. However, its therapeutic application is limited by its photosensitivity and solubility. To overcome these challenges, RESV was encapsulated in a new nano-in-microparticle system comprised of chitosan nanoparticles incorporated into hyaluronic acid and alginate microparticles (RESV-MNP). RESV-MNP exhibited spherical morphology (similar to 2 mu m) and encapsulation efficiency of 79 %, releasing about 41 % of RESV within 24 h, showing a prolonged release profile compared to the free drug. Additionally, RESV-MNP interacted with porcine mucin in an acid environment. RESV-MNP showed no toxicity against AGS/MKN-74 cell lines in vitro and in acute toxicity tests using Galleria mellonella and hemolysis. RESV-MNP presented a minimum inhibitory and bactericidal concentration (MIC/MBC) of 3.9 mu g/mL, eradicating H. pylori after 24 h. At 2xMIC, RESV-MNP completely eradicated H. pylori biofilm. In an in vitro infection assay, RESV-MNP reduced H. pylori load. The formulation effectively reduced the mortality rate of H. pylori-infected larvae in the G. mellonella model. Furthermore, RESV-MNP demonstrated gastroprotective effects, reducing the extent and severity of indomethacin-gastric lesions in rats. (AU) | |
| Processo FAPESP: | 19/09597-6 - Micropartículas gastrorretentivas contendo nanopartículas de trans resveratrol aplicadas ao tratamento de infecções por Helicobacter pylori |
| Beneficiário: | Larissa Sposito |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 21/11681-5 - Avaliação da atividade de micropartículas contendo nanopartículas de trans- resveratrol contra cepas clínicas de Helicobacter pylori: estudo in vitro |
| Beneficiário: | Larissa Sposito |
| Modalidade de apoio: | Bolsas no Exterior - Estágio de Pesquisa - Doutorado |